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Abstract The uptake of selective estrogen receptor modula-
tors (SERMs) and aromatase inhibitors (AIs) for the primary
prevention of breast cancer is low, despite their proven effica-
cy in several randomized clinical trials. This review summa-
rizes the latest data on physicians’ and women’s barriers to
breast cancer preventive therapy. Physicians’ challenges in-
clude: identifying suitable candidates for preventive therapy,
inadequate training and confidence in risk assessment and
counselling, insufficient knowledge of risk-reducing medica-
tions, and lack of time. High-risk women fear medication side
effects, and they often weigh experiences of others more
heavily than statistical probabilities to guide their decision-
making. Despite decision aid interventions to help women
make an informed decision, acceptance of preventive therapy
will remain low until: risk/benefit profiles are more favorable,
physicians are better educated and skilled in having these dis-
cussions, and suitable biomarkers to monitor drug efficacy
and better clinical risk prediction models to assess true indi-
vidual risk are available.
Keywords Breast cancer . Chemoprevention . Preventive
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Introduction
Two selective estrogen receptor modulators (SERMs), tamox-
ifen and raloxifene, are FDA-approved for the primary pre-
vention of breast cancer—tamoxifen for both pre- and post-
menopausal women, and raloxifene for post-menopausal
women only [1•, 2]. Two aromatase inhibitors (AIs) that are
not yet FDA-approved, exemestane and anastrozole, have
been evaluated for breast cancer prevention in post-
menopausal women only [1•, 3]. Although an estimated
15 % of high-risk American women aged 35–79 years are
eligible for breast cancer preventive therapy [4], <5 % who
are offered this option accept it [5]. Reasons for the low uptake
of SERMs and AIs by high-risk women, and primary care
physicians’ reluctance to recommend or prescribe it are
multi-factorial. In this review, we will explore the latest data
on both physicians’ and high-risk women’s barriers to the
uptake of breast cancer preventive therapy. Future directions
and strategies to improve uptake will be discussed using the
ABC (Agents-Biomarkers-Cohorts) paradigm: effective non-
toxic Agents, intermediary Biomarkers to assess drug efficacy,
and better identification of high-risk Cohorts using clinical
risk prediction models [6•].
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Risk-Reduction Therapies for Primary Prevention
of Breast Cancer
SERMs and AIs have been evaluated for the primary preven-
tion of breast cancer in women aged ≥35 years in several
randomized clinical trials [1•]. Women aged ≥35 with a life
expectancy of ≥10 years and a 5-year Gail risk score ≥1.66 %
or a personal history of lobular carcinoma in-situ (LCIS) may
be considered for risk-reducing pharmacotherapy.
The NSABP Breast Cancer Prevention Trial (BCPT P-1)
randomized healthy pre- and post-menopausal women aged
35 years and older with a 5-year Gail model risk score of
≥1.66% or a history of LCIS to receive tamoxifen 20mg daily
for 5 years versus placebo. Results demonstrated that treat-
ment with tamoxifen significantly reduced the risk of invasive
and noninvasive breast cancer by 49 and 50 %, respectively
[7]. The reduction in breast cancer incidence was most pro-
nounced in women with a history of LCIS (56 %) and atypical
hyperplasia (AH) (86 %). Tamoxifen reduced the risk of ER-
positive tumors, but showed no significant effect on ER-
negative tumors. Significant toxicities experienced in the ta-
moxifen group were mostly stratified to women over the age
of 50. These included hot flashes, invasive endometrial cancer
(RR = 2.53; 95 % CI 1.35–4.97), and cataract formation
(RR = 1.57). An increased incidence of thromboembolic
events, including stroke (RR = 1.45; 95%CI 0.93–2.77), deep
vein thrombosis (RR = 1.60; 95 % CI 0.91–2.86), and pulmo-
nary embolism (RR = 3.01; 95 % CI 1.15–9.27) was also ob-
served, with higher risk associated with those aged >50 years
[7]. In 1998, based on the results of the BCPT P-1 study,
tamoxifen received FDA approval as a risk-reduction agent
for women at increased risk of invasive breast cancer [1•].
Additional European studies have evaluated the effect of
tamoxifen in women at average and increased risk of breast
cancer. These studies demonstrated that tamoxifen reduced
ER-positive breast cancers by about one third when compared
to placebo [8–10].
Raloxifene is a second-generation SERM that was initially
shown to be as effective as tamoxifen in reducing the risk of
ER-positive breast cancers [11]. The Study of Tamoxifen and
Raloxifene (STAR P-2) trial compared the two agents in
healthy, high-risk post-menopausal women. The two treat-
ment groups showed similar reduction in breast cancer inci-
dence. Women treated with raloxifene experienced fewer
thromboembolic events and cataracts and non-statistically sig-
nificant lower rates of endometrial cancer. Updated results
following the original report demonstrated that raloxifene
was 76 % as effective as tamoxifen in reducing the overall
risk of invasive disease (RR = 1.24; 95 % CI 1.05–1.47). In
2007, raloxifene was FDA-approved as a breast cancer risk-
reduction agent [1•].
TwoAIs, exemestane and anastrozole, have been evaluated
for the primary prevention of breast cancer in post-
menopausal women. In a randomized, placebo-controlled tri-
al, exemestane significantly reduced invasive breast cancers
(RR = 0.65; 95 % CI 0.18–0.70) without the toxicities (throm-
boembolic, cancer events) associated with SERM therapy [3].
Arthralgias and menopausal symptoms, including hot flashes,
were the main adverse events in women taking exemestane,
but women’s quality of life was minimally affected, although
age-related bone loss worsened despite adequate intake of
calcium and Vitamin D [12, 13].
Similar to theMAP.3 trial, the IBIS-II trial compared the AI
anastrozole to placebo, demonstrating a significant decrease in
risk of invasive breast cancer and a reduction in ER-positive
tumors by 50 and 58 %, respectively [14]. Overall, data re-
garding the use of AIs as risk-reduction therapy for breast
cancer are limited to post-menopausal women with a Gail risk
score of >1.66 % or personal history of LCIS. The benefits
and risks of AIs in comparison to tamoxifen and raloxifene
have not been directly evaluated.
Physicians’ Barriers
Despite the large number of women who qualify for breast
cancer preventive therapy and the US Preventive Services
Task Force’s recommendation [15] to counsel at-risk women
aged ≥35 years (B recommendation) with a 5-year risk of
>3 % where benefit outweighs risk, many are not offered this
option [4]. A cross-sectional, web-based survey of physicians
[16] revealed that only 13 % of providers had recommended
or prescribed preventive therapy (8 % family medicine, 9 %
internal medicine, 30 % gynecology).
A major barrier to discussing or prescribing preventive
therapy is lack of confidence in identifying suitable high-risk
patients. Primary care physicians (PCPs) are often the first
contact person for a woman who wants to discuss her family
history and concerns about preventing breast cancer, and
PCPs consider it their responsibility to assess breast cancer
risk [17, 18]. They are comfortable with taking a family his-
tory, yet often neglect to ask about reproductive history or
history of abnormal breast biopsies [17]. Women with breast
biopsies that impart a significantly increased risk of breast
cancer (AH, LCIS) are more inclined to consider preventive
therapy, yet they are not often identified as potential candi-
dates [19]. Most PCPs have never used the Gail model [20],
which is currently the best available tool to identify suitable
candidates for preventive therapy [16, 17]. In a cross-sectional
survey of 300 PCPs, only 37 and 33% of internists and family
physicians, respectively, reported ever using the Gail model,
as compared to 60 % of gynecologists [16].
Other factors that prevent physicians from discussing pre-
ventive therapy with high-risk women include: lack of knowl-
edge and insufficient training in risk counselling (i.e., oncol-
ogists are better trained) [17, 21], lack of knowledge of risk-
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reducing medication options [21], and concerns with medica-
tion side effects [22•].
Physicians are more comfortable advising about lifestyle
modifications (e.g., weight reduction, exercise, and reducing
alcohol intake), which according to observational studies may
reduce breast cancer risk by up to 30 % [23•]. It is acknowl-
edged that physicians’ recommendations are influential on
women’s uptake of preventive screening maneuvers [24],
and acceptance of risk-reduction therapies [25]. However,
time constraints in a typical 15-min clinical encounter makes
it challenging for front-line clinicians to take a thorough fam-
ily history, a history of breast cancer risk factors, including
previous abnormal biopsies and use risk-assessment tools,
much less counsel about the risks and benefits of preventive
therapy.
Other factors that steer physicians away from
recommending preventive therapy include the lack of evi-
dence of a decrease in breast cancer-specific and all-cause
mortality [6•], concerns about the lack of validated intermedi-
ary biomarkers to monitor efficacy of treatment (unlike car-
diovascular disease prevention with low-density lipoprotein
(LDL) as a biomarker to guide statin use) [22•], and the fact
that certain preventive therapies (AIs) are off-label [6•].
Women’s Barriers
The acceptance of breast cancer risk-reduction therapy is low,
with significantly higher uptake rates in clinical trials (25.2 %)
than in non-trial settings (8.7 %; p < 0.0001) [26, 27]. Factors
influencing women’s decision-making include: fear of side
effects, knowledge and beliefs/concerns about preventive
medications, confusion between chemotherapy and chemo-
prevention, cost, and lack of validated biomarkers to monitor
drug efficacy.
Fear of Side Effects
The most important barrier to accepting breast cancer pre-
ventive therapy by high-risk women is fear and concern
about medication side effects. The most feared side effects
are endometrial cancer, risk of blood clots and strokes
(SERMS), and decrease in bone mineral density (AIs)
[26–28]. Women are also concerned about more common
adverse effects, such as hot flashes, other menopausal
symptoms, and musculoskeletal and urogenital symptoms,
which are medically Bless serious,^ but can negatively
affect day-to-day activities and overall quality of life
[29]. Some high-risk menopausal women are reluctant to
give up hormonal replacement for preventive therapy
[26]. Some women decline preventive therapy because
they consider the risk of medication side effects more
concerning than the risk of developing breast cancer [30,
31]. Decision aids or educational interventions advising
women on the risks and benefits of preventive therapy
may result in women becoming less inclined to start it
[5, 32]. Even when women receive balanced risk/benefit
profiles, their perception of developing medication side
effects is over 40 % [6•, 27, 28].
Knowledge and Beliefs About Preventive Therapy
Awareness of the availability of breast cancer preventive ther-
apy is limited [33], even among a group of highly educated
women [34]. Of those who are aware, many doubt the efficacy
of SERMS or AIs in reducing breast cancer risk [27, 28, 32,
33]. In a Canadian study, high-risk women demonstrated in-
terest in preventive therapy (62–67 % self-reported likelihood
of taking it in the next 5 years), but required strong evidence of
its efficacy and belief that side effects would be tolerable.
They were more likely to take medication if they were
Bproactive^ in health-related matters [30]. Women less likely
to take preventive therapy were often strongly influenced by
family members, relatives, or close friends who had experi-
enced adverse side effects or developed recurrent breast can-
cer while taking tamoxifen as adjuvant therapy [27, 29].
Preventive Therapy (Chemoprevention) Versus
Chemotherapy
Chemoprevention is often confused with chemotherapy [26,
28, 30], especially since many women view tamoxifen as a
Bbreast cancer drug^ for recurrent disease [29] .
Unsurprisingly, some women cited fear of side effects, such
as hair loss, nausea, and vomiting, which are associated with
chemotherapy [28, 29, 35].
Concerns About Medications
A general aversion to medications is another important barrier
to preventive therapy. Many women view medications as
Bunnatural^ [30] and decline to take them unless they are
deemed Bnecessary^ for treatment [35], rather than for preven-
tion [36]. The BHRT fiasco^ has also been cited as a strong
influencer against medications [30]. Some women are afraid
of taking medications or swallowing pills [30], and over 90 %
of high-risk women would choose topical tamoxifen (gel
form) over oral pills, to avoid systemic effects [34]. Daily pill
use for 5 years is also burdensome [34, 39], andmay serve as a
constant reminder of breast cancer risk [29, 35]. Older women
with comorbidities are also concerned about the inconve-
nience of taking additional pills and the possibility of drug
interactions with their other medications [33, 34].
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Socio-Demographics/Social Determinants of Health
Socio-demographic factors such as age, race, education, in-
come or employment status, insurance status, and costs have
not been associated with lower uptake rates [5, 26]. In earlier
studies before Obamacare (Affordable Care Act), cost and
health insurance coverage were important obstacles, especial-
ly for low-incomewomen [33, 36]. Since September 2014, the
Affordable Care Act has made tamoxifen/raloxifene risk-
reduction therapy affordable since no copayment or deduct-
ible is required. However, its impact on uptake has yet to be
determined [37].
Other Barriers to Preventive Therapy
Some women report doubting risk calculation scores, because
they worry that not all risk factors (such as breast density) are
taken into account in these calculations [38]. Another barrier
is the inability to prospectively identify women who might
develop ER-positive versus ER-negative tumors [27]. The ab-
sence of validated intermediary biomarkers to assess response
to medication as an indicator of risk-reduction [39], analogous
to LDL levels to determine response to statins, is a significant
barrier [22•, 27].
Factors Associated With Higher Uptake
Women with a history of breast lesions imparting an increased
breast cancer risk (atypical ductal hyperplasia or LCIS) [26]
and with a Gail score >6 % are more likely to accept preven-
tive therapy [27, 28]. Physicians’ recommendation for preven-
tive therapy is influential in guiding women’s decision-
making [25, 26, 30]. Women with a higher perceived personal
risk of developing breast cancer [5, 26, 39], or higher anxiety
around their perceived risk, are also more likely to accept the
benefits of preventive therapy over the perceived risks [40]. A
summary of factors associated with high-risk women’s uptake
of breast cancer preventive therapy is presented in Table 1.
Discussion
An estimated 10 million American women are eligible for
breast cancer chemoprevention [4], yet <5 % who are offered
this option accept it [5, 22•]. Reasons for the low uptake of
preventive therapy by high-risk women (see Table 1), and
primary care physicians’ reluctance to recommend or pre-
scribe it, are multi-factorial. The most common barrier to
accepting preventive therapy is the fear of medication side
effects, including life threatening but rare risks, such as throm-
boembolic events and endometrial cancer, and more common,
but still infrequent ones, such as menopausal and musculo-
skeletal symptoms [26–29]. Acceptance or rejection of breast
cancer preventive therapy by high-risk women is a
Bpreference-sensitive decision,^ [5, 35] and involves complex
risk-benefit trade-offs [32, 35]. Qualitative studies revealed
that high-risk women initially use all available information
from their Gail risk score and risk/benefit profiles from deci-
sion aids or educational interventions to help in their decision-
making, but their final choice is guided primarily by the ex-
periences of significant others. Close family members and/or
friends who have undergone breast biopsies, chemotherapy, or
risk-reduction therapy impart experiences that ultimately
shaped the attitudes and beliefs of high-risk women regarding
breast cancer, personal risks, and medication use in general
[35, 36].
Women are motivated to consider preventive therapy when
they feel highly vulnerable, such as when they have physical
signs and symptoms or abnormal mammographic findings
[36]. High-risk women weigh the risk/benefits by evaluating
howmedication side effects might impact their daily lives, and
which events (i.e., developing cancer or treatment side effects)
would be experientially worse [5, 30, 35, 36]. Since women’s
decision-making is not based exclusively on evidence-based
findings [30, 35, 36], this partly explains why decision support
interventions have had limited success in increasing preven-
tive therapy uptake rates [22•]. This also explains why a strong
patient-provider relationship may facilitate discussions about
preventive therapy, when a PCP not only counsels using ob-
jective risk estimates but also takes into account a woman’s
values and preferences in the shared decision-making process
[41, 42].
PCPs’ difficulty in identifying suitable high-risk candidates
has been cited as one barrier to discussing or prescribing
breast cancer preventive therapy [27]. To address this gap,
support tools for providers have been created [43•] with clear-
er messages about the ideal candidates for preventive therapy
as demonstrated by the USPSTF chemoprevention consensus
statement: cohorts of women with the highest benefit/risk ra-
tio, such as those under 50 years of age, with a strong family
history of breast cancer or a personal history of AH [44].
Physicians prefer electronically based, easy-to-use point of
care tools, and the modified Gail or breast cancer risk-
assessment tool (BCRAT) is one such tool [45]. It has been
validated in white, Asian, and African American populations
[46–48]. It is the best tool to identify candidates for preventive
therapy, but is not effective at categorizing candidates for ge-
netic testing or enhanced screening. The Breast Referral
Screening Tool (B-RST) [49] and the Tyrer-Cuzick (IBIS)
Tool [50] are better suited for such indications, respectively.
These latter tools may be used to further stratify high-risk
women, who could benefit from other risk-reduction strate-
gies, such as lifestyle changes, prophylactic mastectomy, and/
or prophylactic oophorectomy [22•, 23•, 51, 52].
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Despite decision aid interventions using currently available
risk calculators and discussions with PCPs about the risk/
benefits of preventive therapy to help women make an in-
formed decision, its acceptance will remain low, until medica-
tions have fewer side effects, biomarkers can be identified to
monitor drug efficacy, and newer clinical risk prediction
models can provide true individual risk versus population risk.
Future Directions
Future directions and strategies to improve preventive therapy
uptake requires attention to the ABC (Agents-Biomarkers-
Cohorts) paradigm: the availability of effective non-toxic
Agents, effective intermediary Biomarkers to assess response to
medication, and better identification of high-risk Cohorts [6•].
New research on genome-wide association studies has led
to more recent understanding of combined association of sin-
gle nucleotide polymorphisms (SNPs) with increased risk for
developing breast cancer. Incorporating SNP information into
clinical risk prediction models has the ability to better inform
individual risk, which in turn could improve uptake of preven-
tive therapy going forward [53].
Overcoming a major obstacle to breast cancer pharmaco-
therapy necessitates improving its side effect profile. One
strategy might be to either offer low- or intermittent doses of
existing preventive agents, which would cause fewer adverse
side effects [6•]. Clinical trials and observational studies are
being investigated to test the efficacy and effects of varying
doses of tamoxifen (1, 5, or 10 mg daily vs. 10–20 mg weekly
vs. standard 20 mg daily dose) on systemic biomarkers, such
as lipid and insulin-like growth factors, and tissue biomarkers,
like Ki-67 [6•, 54]. Another approach is offering a topical
form of tamoxifen (4-OHT) that can be applied directly onto
the breast, and which is expected to decrease systemic effects
[6•, 54]. Repurposed drugs, such as aspirin, metformin,
NSAIDS, vitamin D, retinoids, statins, and bisphosphonates
[6•, 41], are being investigated as potential preventive
therapeutic agents with better safety profiles than SERMs
and AIs, and possible effectiveness against ER-negative tu-
mors as well [51, 55].
The lack of surrogate biomarkers is another obstacle to the
uptake of preventive therapy by high-risk women.
Mammographic density has been identified as a risk factor
for breast cancer, and it is now being investigated as a bio-
marker of response to breast cancer chemoprevention [22•,
41]. Enrollment in the IBIS-I trial caused a significant de-
crease (p < 0.001) in mammographic density after 18 months
on tamoxifen, as compared to placebo [56], with a 10 % de-
crease in mammographic density associated with a 63 % re-
duction in breast cancer risk [57].
To realistically decrease breast cancer incidence rates,
non-pharmacologic interventions such as lifestyle modifi-
cations, which may reduce breast cancer risk by 30 %,
should be offered alongside chemoprevention [22•, 23•,
51, 52]. Excess weight has been linked to the develop-
ment of both ER-positive and ER-negative tumors, and a
5–10 % weight loss in the years before and shortly after
menopause has been associated with a 25–50 % reduction
in breast cancer risk [51]. These lifestyle recommenda-
tions for breast cancer risk-reduction also reduce the inci-
dence of diabetes, hypertension, heart disease, and de-
mentia [22•, 23•, 51, 52]. PCPs are well positioned to
counsel and encourage healthy lifestyle changes, so that
breast cancer risk and concurrent co-morbid conditions
can be addressed simultaneously. High-risk women are
largely receptive to breast cancer screening [24], and with
the future availability of biomarkers and less toxic medi-
cations, preventive therapy may become more widely
accepted.
Conclusions
The uptake of SERMs and AIs for the primary prevention of
breast cancer is low, despite its proven efficacy in randomized
Table 1 Factors associated with
uptake of breast cancer preventive
therapy
Lower uptake Higher uptake
Fear and concerns about side effects (both rare and
medically less serious ones that can affect quality
of life)
Abnormal biopsy results (e.g., women with atypical
hyperplasia/LCIS vs. high-risk women from the
general population)
Confusion between chemoprevention vs.
chemotherapy
Higher perceived personal risk of breast cancer
Personal, family, or close friends’ experiences with
breast cancer, chemoprevention, and
chemotherapy
Fewer concerns about medication side effects and
prevention trials
Greater knowledge of medication side effects Physician recommendation
Cost/no health insurance coverage
Uncertainty about breast cancer risk and risk-
assessment models
Daily pill burden
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clinical trials over the past decade. PCPs have difficulty iden-
tifying suitable candidates, lack knowledge about therapeutic
options and confidence to counsel about preventive therapy.
High-risk women’s decision to accept chemoprevention is
complex, and their choice often reflects lived experiences,
rather than statistical probabilities. Despite decision aid inter-
ventions to help women make an informed choice about pre-
ventive therapy, acceptance will remain low until physicians
are better educated and more skilled in having these discus-
sions, medications are safer and better tolerated, suitable bio-
markers to monitor drug efficacy are identified, and clinical
risk predictionmodels using genomic information can provide
true individual risk. Risk/benefit counselling about preventive
therapy, alongside lifestyle modifications to high-risk women,
will simultaneously address breast cancer risk-reduction, and
the prevention of co-morbidities, such as diabetes and cardio-
vascular disease.
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